Early results from a multi-centre trial indicate that BI-8721 may slow cognitive decline and reduce amyloid biomarkers in …
Early results from a multi-centre trial indicate that BI-8721 may slow cognitive decline and reduce amyloid biomarkers in …
First 16-week data from the APEX Part A trial reveal APG777 could raise the bar for biologics in …
Company Overview and Focus Biodexa Pharmaceuticals PLC, a clinical-stage biotechnology company dedicated to developing innovative treatments for diseases …
Continued program expansion strengthens potential to deliver an all-oral, pan-genotypic next-generation HCV therapy.
Major investment strengthens pharmaceutical supply chain resilience and advances green manufacturing practices in North America.
Inclusion in major indexes highlights aTyr’s expanding biotech footprint and investor recognition amid advancing therapeutic pipeline.
Analysts predict transformative biotherapies to lead future cancer treatment breakthroughs, with Oncolytics poised for key role.
Dual GLP-1 and GIP receptor agonist VK2735 moves into pivotal trials targeting robust weight loss and glycemic control …
Novel agent ENT-03 demonstrates promising metabolic improvements and safety in first-in-human study, setting stage for further development in …
CEO Lamballe highlights strategic advances, upcoming trial readouts, and expansion of microbiome ecosystem therapies pipeline.
Already a subscriber? Log in